Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections

Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections

Author Sader, Helio S. Autor UNIFESP Google Scholar
Jones, Ronald N. Google Scholar
Institution JMI Labs
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
Abstract Cefdinir is an oral third-generation cephalosporin (also known as an advanced-spectrum or generation cephem) with good in vitro activity against the pathogens responsible for community-acquired respiratory tract infections and uncomplicated skin and skin structure infections. the drug distributes very well in respiratory tract tissues and fluids, as well as skin blisters and ear fluids; its pharmacokinetic profile allows once- or twice-daily administration. Oral cefdinir 300 mg twice daily or 600 mg once daily in adults and adolescents, or 14 mg/kg/day in one or two daily doses in pediatric patients, administered for 5 or 10 days, has shown good clinical and bacteriological efficacy, at least equivalent to that of other oral agents in randomized controlled trials conducted in patients with community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, sinusitis, acute otitis media, pharyngitis and uncomplicated skin and skin structure infections. Cefdinir is well tolerated and the oral suspension has shown superior taste or palatability over other comparator oral antimicrobial agents. Thus, cefdinir continues to represent an important cephalosporin option for the treatment of adult, adolescent and pediatric patients with mild or moderate respiratory tract or cutaneous infections, especially in areas with elevated rates of beta-lactamase production in Haemophilus influenzae and where resistance to other commonly used agents has emerged (e.g., macrolides, penicillins, tetracyclines, fluoroquinolones and trimethoprim-sulfamethoxazole).
Keywords acute otitis media
cefdinir
group A streptococcal pharyngitis
Haemophilus influenzae
oral cephalosporin
palatability
respiratory tract infections
skin and skin structure infections
Streptococcus pneumoniae
toleration
uSSTI
Language English
Date 2007-02-01
Published in Expert Review of Anti-infective Therapy. London: Expert Reviews, v. 5, n. 1, p. 29-43, 2007.
ISSN 1478-7210 (Sherpa/Romeo, impact factor)
Publisher Expert Reviews
Extent 29-43
Origin http://dx.doi.org/10.1586/14787210.5.1.29
Access rights Closed access
Type Article
Web of Science ID WOS:000253781000013
URI http://repositorio.unifesp.br/handle/11600/29507

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account